HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks

Around 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2). In this setting, anti-HER2-targeted agents are the cornerstone of cancer therapeutic strategies. This includes monoclonal antibodies, tyrosine kinase inhibitors (TKIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandó, Pablo, Waisberg, Federico, Pasquinelli, Rosario, Rivero, Sergio, Ostinelli, Alexis, Perazzo, Florencia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948634/
https://www.ncbi.nlm.nih.gov/pubmed/36844609
http://dx.doi.org/10.2147/OTT.S335934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948634/
https://www.ncbi.nlm.nih.gov/pubmed/36844609
http://dx.doi.org/10.2147/OTT.S335934

Ejemplares similares